Anixa's vaccine, developed with Cleveland Clinic and NCI, uses a nucleic acid encoding AMHR2’s extracellular domain. Learn how to trade volatility during Q1 earnings season, live with Matt Maley ...

1 Specifically, the application covers the use of targeting Anti-Mullerian Hormone Receptor, Type II (AMHR2). While a Notice of Allowance does not guarantee registration of the patent, it is a step in ...

The patent includes broad claims related to methods of eliciting an immune response targeting Anti-Mullerian Hormone Receptor, Type II (AMHR2), a promising target for ovarian cancer prevention and ...

The allowed claims include methods of administering an immunogenic composition comprising a nucleic acid encoding the AMHR2 polypeptide, specifically the extracellular domain of human AMHR2 ...

The patent includes broad claims related to methods of eliciting an immune response targeting the Anti-Mullerian Hormone Receptor, Type II (AMHR2), a target for ovarian cancer prevention and ...

The patent includes broad claims related to methods of eliciting an immune response targeting Anti-Mullerian Hormone Receptor, Type II (AMHR2), a promising target for ovarian cancer prevention and ...

The patent includes broad claims related to methods of eliciting an immune response targeting the Anti-Mullerian Hormone Receptor, Type II (AMHR2), a target for ovarian cancer prevention and treatment ...